Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 301 to 308 of 308 results for eq-5d

  1. The social care guidance manual (PMG10)

    The social care guidance manual

  2. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems)

  3. Research recommendations

    complications, pulmonary function and quality of life (including assessment by EQ-5D). CG121/3

  4. Sofosbuvir for treating chronic hepatitis C (TA330)

    Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)

  5. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.

  6. Methods for the development of NICE public health guidance (third edition) (PMG4)

    Methods for the development of NICE public health guidance (third edition)

  7. A new instrument for consideration of a broader range of benefits for people, their families and carers

    For the last three years, NICE has been part of a research project investigating how quality of life measures used to evaluate healthcare treatments such as drugs can be extended into areas of social care and public health

  8. Researchers wanted to study the public's views of health-related quality of life

    Applications close on Wednesday 4 March 2020